Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOX-E36 in Type 2 Diabetes with Albuminuria
NCT01547897Phase 2Completed
- Sponsor
- TME Pharma
- Start
- Mar 2012
- Primary completion
- Sep 2013
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 5
01
Overview
A Phase 2 trial of emapticap pegol in diabetic nephropathy (DN), sponsored by TME Pharma. Started Mar 2012; status: completed.
02
Drugs
emapticap pegol
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT01547897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01547897.